Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NeoDynamics today announced it would participate in a Q&A session with HC Andersen Capital on September 21 to discuss the company's planned US launch of its innovative pulse biopsy system NeoNavia® after receiving approval from the US Food and Drug Administration, FDA, in September 2022.
"The FDA approval for NeoNavia earlier this month is a critical step for NeoDynamics as the US represents potentially the largest market for the product valued at $830 million by 2025," said Anna Eriksrud, CEO of NeoDynamics. "The company is moving quickly to push its US strategy, which is similar to the plan that is now being executed on in Europe."
NeoDynamics's CEO Anna Eriksrud, and CFO Aaron Wong will present at the Q&A.
Participants can register here (https://hcandersencapital643.clickmeeting.com/neodynamics-q-a-session-with-ceo-anna-eriksrud/register?_gl=1*qgq7op*_ga*ODIyODA1ODA4LjE2NTk0MzE4NDc.*_ga_K7H94QHX99*MTY2MzA1OTQ3Ny40Mi4xLjE2NjMwNTk3OTIuNDMuMC4w&_ga=2.188915051.131503173.1663059478-822805808.1659431847) to join the event on September 21 at 11:00 to 11.30 CEST.